Oliver Nussbaumer

Oliver Nussbaumer currently serves as a Non Executive Director at IMU Biosciences since September 2023. Previously, Oliver held the position of R&D Distinguished Fellow and Executive Scientific Director of Cell Therapy Innovations at Takeda from April 2022 to April 2023. As a Scientific Co-Founder of Adaptate Biotherapeutics from August 2019 to May 2022 and Vice President of Immunology at GammaDelta Therapeutics from August 2016 to April 2022, Oliver contributed significantly to the field. At King's College London, Oliver progressed from Postdoctoral Research Associate to Head of Immunology and Head of Cell Research from June 2013 to May 2021, focusing on the human innate immune system and γδ T cells. Prior experiences include a Visiting Post Doctoral Fellow role at The Francis Crick Institute and a PhD focused on human dendritic cells at Oncotyrol. Academic qualifications include a PhD in Medical Science from Medizinische Universität Innsbruck and master's and bachelor's degrees in Molecular Biology and Biology, respectively, from Universität Innsbruck.